Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05645692 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
A Phase 2 study of Urothelial Cancer, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 2
- Development phase
- 204
- Enrollment target
- 20
- Study locations
NCT05645692 is a Phase 2 study of Urothelial Cancer that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 204 participants, below the 566-participant average among 25 other Urothelial Cancer trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT05645692, a Phase 2 study of Urothelial Cancer, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 204 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety of tobemstomig alone or in combination with tiragolumab compared with atezolizumab in participants with previously untreated, locally advanced or metastatic urothelial cancer (mUC) who are ineligible to receive a platinum containing chemotherapy.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Tiragolumab
- DRUG Tobemstomig
Study Locations (20)
Other
- Beijing Cancer Hospital - Beijing
- West China Hospital - Sichuan University - Chengdu
- Sun yat-sen University Cancer Center - Guangzhou
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine - Shanghai
- Aarhus Universitetshospital - Aarhus N
- Herlev Hospital - Herlev
- Centre Leon Berard - Lyon
- Gustave Roussy - Villejuif
- Krankenhaus Martha-Maria Halle-Dölau, Klinik für Urologie - Halle
- Martini-Klinik am UKE GmbH - Hamburg
South Australia
- Lyell McEwin Hospital - Adelaide
- ICON Cancer Care Adelaide - Kurralta Park
São Paulo
- *X*CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia - Santo André
- Hospital Alemao Oswaldo Cruz - São Paulo
Ohio
- Cleveland Clinic - Cleveland
Texas
- MD Anderson Cancer Center - Houston
New South Wales
- Macquarie University Hospital - Macquarie Park
Paraná
- Hospital Universitario Evangelico De Curitiba - Curitiba
Rio Grande do Sul
- Hospital das Clinicas - UFRGS - Porto Alegre
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2023-04-13 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05645692
The ClinicalTrials.gov registry entry for NCT05645692 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 566-participant average among 25 other Urothelial Cancer trials with a reported enrollment target (64% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urothelial Cancer appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.
NCT05645692 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, South Australia, São Paulo.
Frequently Asked Questions
What is clinical trial NCT05645692 about?
NCT05645692 is a clinical study titled "A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer". This study will evaluate the safety of tobemstomig alone or in combination with tiragolumab compared with atezolizumab in participants with previously untreated, locally advanced or metastatic urothelial cancer (mUC) who are ineligible to receive a platinum containing chemotherapy.
What is the current status of trial NCT05645692?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2023-04-13. Estimated completion is 2026-12-31.
What conditions does trial NCT05645692 study?
This clinical trial studies the following conditions: Urothelial Cancer.
What interventions are being tested in trial NCT05645692?
The interventions under investigation include: Atezolizumab (DRUG), Tiragolumab (DRUG), Tobemstomig (DRUG).
Who is sponsoring clinical trial NCT05645692?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05645692 being conducted?
This trial has 20 study locations across Ohio, Texas, New South Wales, South Australia, Paraná. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
RECRUITING · Phase 2
-
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
RECRUITING · Phase 2
-
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
RECRUITING · Phase 2
-
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.